

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025**SECTION 1. IDENTIFICATION**

Product name : XOFLUZA Reconst. Oral Susp. 2 mg/ml

Product code : RO719-1686/F20-00

**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : 1 DNA Way  
South San Francisco, CA 94080  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

In case of emergencies: : US CHEMTREC PHONE (800)-424-9300

**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)****Hazards for the product as supplied**

Carcinogenicity : Category 1A

**Other hazards**

None known.

**GHS label elements**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H350 May cause cancer.

Precautionary Statements :

**Prevention:**

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read and understood.

P280 Wear protective gloves, protective clothing, eye protection and face protection.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**
Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/attention.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS No./Unique ID	Concentration (% w/w)	Trade secret
Baloxavir Marboxil	1985606-14-1*	0.2	-
D-Mannitol	69-65-8*	6	-
D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-	585-88-6*	3.7	-
Sodium chloride (NaCl)	7647-14-5*	0.3	-
Silica	7631-86-9*	0.2	-
2-Pyrrolidinone, 1-ethenyl-, homopolymer	9003-39-8*	0.1	-
Sucralose	56038-13-2*	0.1	-
Cellulose, 2-hydroxypropyl methyl ether	9004-65-3*	0.03	-
Strawberry Flavour	-	0.01	-
Talc (Mg <sub>3</sub> H <sub>2</sub> (SiO <sub>3</sub> ) <sub>4</sub> )	14807-96-6*	0.01	-
Water	7732-18-5*	89	-

\* Indicates that the identifier is a CAS No.

---

**SECTION 4. FIRST AID MEASURES**

General advice : Do not leave the victim unattended.

If inhaled : If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

- In case of skin contact : Wash off with soap and water.
- In case of eye contact : Remove contact lenses.  
Protect unharmed eye.  
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.
- Most important symptoms and effects, both acute and delayed : May cause cancer.
- Protection of first-aiders : First Aid responders should pay attention to self-protection and use the recommended protective clothing
- Notes to physician : Treat symptomatically.

---

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Unsuitable extinguishing media : High volume water jet
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : Carbon oxides
- Further information : Standard procedure for chemical fires.  
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Refer to protective measures listed in sections 7 and 8.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**
Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Environmental precautions : If the product contaminates rivers and lakes or drains inform respective authorities.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).  
Keep in suitable, closed containers for disposal.

---

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.  
Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Do not freeze.  
Protect from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

Packaging material : Suitable material: Stainless steel, glass

---

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**
**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Silica	7631-86-9	PEL (respirable)	0.05 mg/m <sup>3</sup>	OSHA CARC
		TWA (Respirable dust)	0.05 mg/m <sup>3</sup> (Silica)	NIOSH REL
Baloxavir Marboxil	1985606-14-1	IOEL	0.0025 mg/m <sup>3</sup>	Roche Industrial Hygiene Committee (RIHC)

**Predicted No Effect Concentration (PNEC):**

Substance name	Environmental Compartment	Value
Baloxavir Marboxil	Surface waters	9.2 µg/l
	Remarks: Based on chronic data, Information refers to the main ingredient.	

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025**Personal protective equipment**

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

## Hand protection

In case of contact through splashing:  
Material : Nitrile rubber  
Break through time : > 30 min  
Glove thickness : > 0.11 mm

In case of full contact:  
Material : butyl-rubber  
Break through time : > 480 min  
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.  
Eye protection : Safety glasses  
Skin and body protection : Protective suit  
Hygiene measures : General industrial hygiene practice.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : suspension  
Color : white  
Odor : No data available  
Odor Threshold : No data available  
pH : No data available  
Melting point/ range : No data available  
Boiling point/boiling range : No data available

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Flash point	:	No data available
Evaporation rate	:	No data available
Self-ignition	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, dynamic	:	No data available
Viscosity, kinematic	:	No data available
Explosive properties	:	No data available
Oxidizing properties	:	No data available
Particle characteristics		
Particle Size Distribution	:	Not applicable

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	No dangerous reaction known under conditions of normal use.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Stable under recommended storage conditions. No hazards to be specially mentioned.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Conditions to avoid : No data available

Incompatible materials : Not applicable

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified due to lack of data.

**Components:****Baloxavir Marboxil:**

Acute oral toxicity : LD50 Oral (Rat): &gt; 2,000 mg/kg

**D-Mannitol:**Acute oral toxicity : LD50 Oral (Rat): 13,500 mg/kg  
LD50 Oral (Mouse): 22,000 mg/kgAcute inhalation toxicity : Acute toxicity estimate: > 30 mg/l  
Test atmosphere: dust/mist  
Method: Expert judgmentAcute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Expert judgment**Sodium chloride (NaCl):**

Acute oral toxicity : LD50 Oral (Rat): 3,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 42 mg/l  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 Dermal (Rabbit): &gt; 10,000 mg/kg

**Silica:**Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg  
GLP: yesAcute inhalation toxicity : LC50 (Rat, male and female): > 5.01 mg/l  
Exposure time: 4 h

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Test atmosphere: dust/mist  
Method: OECD Test Guideline 436  
GLP: yes  
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 Dermal (Rabbit): > 5,000 mg/kg  
Method: No information available.  
GLP: No information available.

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Acute oral toxicity : LD50 Oral (Rat): > 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): 5.2 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403

Acute dermal toxicity : Acute toxicity estimate: > 5,001 mg/kg  
Method: Expert judgment

**Sucralose:**

Acute oral toxicity : LD50 Oral (Rat): > 10,000 mg/kg

**Skin corrosion/irritation**

Not classified due to lack of data.

**Components:****Sodium chloride (NaCl):**

Species : Rabbit  
Result : No skin irritation

**Silica:**

Species : Rabbit  
Exposure time : 4 h  
Method : OECD Test Guideline 404  
Result : No skin irritation  
GLP : No information available.

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Species : Rabbit  
Result : No skin irritation

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025**Strawberry Flavour:**

Result : Irritating to skin.

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Remarks : This information is not available.

**Serious eye damage/eye irritation**

Not classified due to lack of data.

**Components:****Sodium chloride (NaCl):**Species : Rabbit  
Result : No eye irritation**Silica:**Species : Rabbit  
Result : No eye irritation  
Exposure time : 24 h  
GLP : no**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**Species : Rabbit  
Result : No eye irritation**Strawberry Flavour:**

Result : Irritating to eyes.

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Remarks : This information is not available.

**Respiratory or skin sensitization****Skin sensitization**

Not classified due to lack of data.

**Respiratory sensitization**

Not classified due to lack of data.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025**Components:****Silica:**

Test Type : Maximization Test  
Species : Guinea pig  
Assessment : Does not cause skin sensitization.  
Method : OECD Test Guideline 406  
Result : Did not cause sensitization on laboratory animals.  
GLP : yes

**Strawberry Flavour:**

Assessment : May cause sensitization by skin contact.

**Germ cell mutagenicity**

Not classified due to lack of data.

**Components:****Baloxavir Marboxil:**

Genotoxicity in vitro : Method: Mutagenicity (Salmonella typhimurium - reverse mutation assay)  
Result: negative

Method: OECD Test Guideline 473  
Result: negative

Genotoxicity in vivo : Method: OECD Test Guideline 474  
Result: negative

**Sodium chloride (NaCl):**

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)  
Metabolic activation: with and without metabolic activation  
Method: Mutagenicity (micronucleus test)  
Result: negative

Genotoxicity in vivo : Test Type: Chromosome aberration test in vitro  
Species: Rat (female)  
Cell type: Bone marrow  
Application Route: Intraperitoneal injection  
Method: OECD Test Guideline 475  
Result: positive

**Silica:**

Genotoxicity in vitro : Test Type: Microbial mutagenesis assay (Ames test)  
Test system: Salmonella typhimurium

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Metabolic activation: with and without metabolic activation  
 Method: OECD Test Guideline 471  
 Result: negative  
 GLP: yes

Test Type: Microbial mutagenesis assay (Ames test)  
 Test system: Escherichia coli  
 Metabolic activation: with and without metabolic activation  
 Method: OECD Test Guideline 471  
 Result: negative  
 GLP: yes

Test Type: In vitro mammalian cell gene mutation test  
 Test system: mouse lymphoma cells  
 Metabolic activation: with and without metabolic activation  
 Method: OECD Test Guideline 490  
 Result: negative  
 GLP: yes

Genotoxicity in vivo : Species: Rat (male)  
 Cell type: Bone marrow  
 Application Route: Oral  
 Method: OECD Test Guideline 475  
 Result: negative  
 GLP: no

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Germ cell mutagenicity - Assessment : Tests on bacterial or mammalian cell cultures did not show mutagenic effects.

**Carcinogenicity**

May cause cancer.

**Components:****D-Mannitol:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-:**

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**Silica:**

Species : Rat, male and female

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Application Route : Oral  
 Exposure time : 2 Years  
 Method : No information available.  
 Result : negative  
 GLP : No information available.

<b>IARC</b>	Group 1: Carcinogenic to humans Silica (Silica dust, crystalline)	7631-86-9
<b>OSHA</b>	OSHA specifically regulated carcinogen Silica (crystalline silica)	7631-86-9
<b>NTP</b>	Known to be human carcinogen Silica (Silica, Crystalline (Respirable Size))	7631-86-9

**Reproductive toxicity**

Not classified due to lack of data.

**Components:****Baloxavir Marboxil:**

Effects on fetal development : Species: Rat  
 Application Route: Oral  
 Dose: 1000 milligram per kilogram  
 Duration of Single Treatment: 12 d  
 Result: No effects on fetal development.

Species: Rabbit  
 Application Route: Oral  
 Dose: 100 milligram per kilogram  
 Duration of Single Treatment: 12 d  
 Result: No effects on fetal development.

**Silica:**

Effects on fertility : Species: Rat, male and female  
 Application Route: Oral  
 Dose: 100, 300, 1000 mg/kg bw/day  
 General Toxicity Parent: NOAEL: >= 1,000 mg/kg body weight  
 General Toxicity F1: NOAEL: >= 1,000 mg/kg body weight  
 Method: OECD Test Guideline 416  
 GLP: yes

Effects on fetal development : Species: Mouse, female  
 Application Route: Oral  
 Dose: 13.4, 62.3, 289, 1340 mg/kg bw/day

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Duration of Single Treatment: 6 - 15 d  
General Toxicity Maternal: LOAEL:  $\geq 1,340$  mg/kg bw/day  
Embryo-fetal toxicity.: NOAEL:  $\geq 1,340$   $\mu\text{g}/\text{kg}$  body weight  
Method: No information available.  
GLP: No information available.

**STOT-single exposure**

Not classified due to lack of data.

**Components:****D-Mannitol:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

**STOT-repeated exposure**

Not classified due to lack of data.

**Components:****D-Mannitol:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025**Repeated dose toxicity****Components:****Baloxavir Marboxil:**

Species : Rat  
NOAEL : 2000 mg/kg bw/day  
Application Route : Oral  
Exposure time : 2 Weeks  
Remarks : Subacute toxicity

**Silica:**

Species : Rat, male and female  
NOEL : 4000 mg/kg  
Application Route : Oral  
Exposure time : 13 Weeks  
Method : OECD Test Guideline 408  
GLP : yes

**Aspiration toxicity**

Not classified due to lack of data.

**Components:****D-Mannitol:**

No data available

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

No data available

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

No data available

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

**Further information**

**Product:**

Remarks : No data available

**Components:**

**D-Mannitol:**

Remarks : Health injuries are not known or expected under normal use.

---

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Baloxavir Marboxil:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 10.6 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

GLP: yes

Remarks: average measured concentration

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
 Date of first issue: 06/15/2025

NOEC (Danio rerio (zebra fish)): 10.6 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

GLP: yes

Remarks: average measured concentration

Toxicity to daphnia and  
other aquatic invertebrates

: EC50 (Daphnia magna (Water flea)): > 17.4 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

GLP: yes

Remarks: measured initial concentration

NOEC (Daphnia magna (Water flea)): 17.4 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: measured initial concentration

Toxicity to algae/aquatic  
plants

: ErC50 (Desmodesmus subspicatus (green algae)): 9.28 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: yes

Remarks: average measured concentration

NOErC (Desmodesmus subspicatus (green algae)): 1.75 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: yes

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Remarks: average measured concentration

EyC50 (Desmodesmus subspicatus (green algae)): 4.76 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

GLP: yes

Remarks: average measured concentration

Toxicity to microorganisms : (activated sludge): Exposure time: 14 d

Method: OECD Test Guideline 301F

GLP: yes

Remarks: no adverse influence on substrate biodegradation

**D-Mannitol:**

Toxicity to fish : LC50 (Fish): &gt; 100 mg/l

Exposure time: 96 h

Toxicity to fish (Chronic toxicity) : &gt; 1 mg/l

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

**Sodium chloride (NaCl):**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 7,650 mg/l  
Exposure time: 96 h

LC50 (Lepomis macrochirus (Bluegill sunfish)): 5,840 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 874 mg/l  
Exposure time: 48 h  
Test Type: static test

LC50 (Daphnia magna (Water flea)): 4,136 mg/l  
Exposure time: 48 h  
Test Type: static test  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50: 2,430 mg/l  
Exposure time: 120 h  
Test Type: static test  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 252 mg/l  
Exposure time: 33 d  
Test Type: flow-through test  
Method: OECD Test Guideline 210  
GLP: no

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia): 314 mg/l  
Exposure time: 21 d  
Test Type: semi-static test  
Method: OECD Test Guideline 211

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Silica:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): >5,000 mg/l  
End point: mortality  
Exposure time: 96 h  
Test Type: static test  
Analytical monitoring: no  
Method: OECD Test Guideline 203  
GLP: no

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): >10,000 mg/l  
End point: Immobilization  
Exposure time: 24 h  
Test Type: static test  
Analytical monitoring: no

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Method: OECD Test Guideline 202

GLP: yes

Toxicity to algae/aquatic plants : EC50 (Desmodesmus subspicatus (green algae)): &gt; 173.1 mg/l

End point: Growth rate

Exposure time: 72 h

Test Type: static test

Analytical monitoring: yes

Method: OECD Test Guideline 201

GLP: yes

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : Lowest Observed Effect Concentration (Daphnia magna (Water flea)): 149.2 mg/l

End point: mortality

Exposure time: 21 d

Test Type: semi-static test

Analytical monitoring: yes

Method: OECD Test Guideline 211

GLP: yes

Toxicity to microorganisms : NOEC (activated sludge): 1,000 mg/l

End point: Respiration inhibition

Exposure time: 3 h

Test Type: static test

Analytical monitoring: no

Method: OECD Test Guideline 209

GLP: yes

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 96 h

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 100,000 mg/l  
Exposure time: 24 h

**Ecotoxicology Assessment**

Acute aquatic toxicity : This product has no known ecotoxicological effects.

Chronic aquatic toxicity : This product has no known ecotoxicological effects.

Toxicity Data on Soil : Not expected to adsorb on soil.

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Other organisms relevant to : No data available  
the environment

**Persistence and degradability****Components:****Baloxavir Marboxil:**

Biodegradability : Result: Not readily biodegradable.

Biodegradation: &lt; 10 %

Exposure time: 28 d

Method: OECD Test Guideline 301F

GLP: yes

Physico-chemical : Method: OECD Test Guideline 301F  
removability  
Remarks: Not abiotically degradable**D-Mannitol:**

Biodegradability : Biodegradation: 68 %

Exposure time: 28 d

**Sodium chloride (NaCl):**Biodegradability : Remarks: The methods for determining biodegradability are  
not applicable to inorganic substances.**Silica:**

Biodegradability : Remarks: Not applicable

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**

Biodegradability : Zahn-Wellens Test  
Biodegradation: < 10 %  
Exposure time: 15 d  
Method: OECD Test Guideline 302B

**Bioaccumulative potential**

**Components:**

**Baloxavir Marboxil:**

Partition coefficient: n-octanol/water : log Pow: 2.24  
Method: calculated, consensus of various QSARs

log Pow: 2.46 (77 °F / 25 °C)

pH: 5

Method: OECD Test Guideline 117

GLP: yes

log Pow: 2.45 (77 °F / 25 °C)

pH: 7

Method: OECD Test Guideline 117

GLP: yes

log Pow: 2.46 (77 °F / 25 °C)

pH: 9

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Method: OECD Test Guideline 117

GLP: yes

**D-Mannitol:**Partition coefficient: n-  
octanol/water : log Pow: -3.10**D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-:**Partition coefficient: n-  
octanol/water : Remarks: No data available**Sodium chloride (NaCl):**Partition coefficient: n-  
octanol/water : Remarks: Not applicable**Silica:**Partition coefficient: n-  
octanol/water : Remarks: Not applicable**2-Pyrrolidinone, 1-ethenyl-, homopolymer:**Partition coefficient: n-  
octanol/water : Remarks: No data available**Sucralose:**Partition coefficient: n-  
octanol/water : Remarks: No data available**Cellulose, 2-hydroxypropyl methyl ether:**Partition coefficient: n-  
octanol/water : Remarks: No data available

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

**Strawberry Flavour:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Partition coefficient: n-octanol/water : Remarks: No data available

**Water:**

Partition coefficient: n-octanol/water : Remarks: No data available

**Mobility in soil**

No data available

**Other adverse effects**

**Product:**

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82  
Protection of Stratospheric Ozone - CAA Section 602 Class I  
Substances

Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

## XOFLUZA Reconst. Oral Susp. 2 mg/ml

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Additional ecological information : No data available

### Components:

#### **Baloxavir Marboxil:**

Results of PBT and vPvB assessment : Not persistent, bioaccumulative, and toxic (PBT).

Endocrine disrupting potential : Does not have endocrine disrupting properties.

#### **Talc (Mg<sub>3</sub>H<sub>2</sub>(SiO<sub>3</sub>)<sub>4</sub>):**

Adsorbed organic bound halogens (AOX) : Remarks: Not applicable

Additional ecological information : No data available

---

### SECTION 13. DISPOSAL CONSIDERATIONS

#### **Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.

---

### SECTION 14. TRANSPORT INFORMATION

#### **International Regulations**

**UNRTDG**

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to IMO instruments**

Not applicable

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**Special precautions for user**Remarks : Not dangerous goods in the meaning of ADR/RID, ADN,  
IMDG-Code, ICAO/IATA-DGR

---

**SECTION 15. REGULATORY INFORMATION****CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Carcinogenicity**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM I Intermediate or Final VOC's (40 CFR 60.489).

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

**Clean Water Act**

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

**US State Regulations**

**Massachusetts Right To Know**

No components are subject to the Massachusetts Right to Know Act.

**Pennsylvania Right To Know**

Water	7732-18-5
D-Mannitol	69-65-8
D-Glucitol, 4-O-.alpha.-D-glucopyranosyl-	585-88-6

**Maine Chemicals of High Concern**

Silica	7631-86-9
--------	-----------

**Vermont Chemicals of High Concern**

Product does not contain any listed chemicals

**Washington Chemicals of High Concern**

Product does not contain any listed chemicals

**California Prop. 65**

WARNING: This product can expose you to chemicals including Silica, which is/are known to the State of California to cause cancer. For more information go to [www.P65Warnings.ca.gov](http://www.P65Warnings.ca.gov).

**California Regulated Carcinogens**

Silica	7631-86-9
--------	-----------

**The ingredients of this product are reported in the following inventories:**

- AU AIIC : Not in compliance with the inventory
- CA. DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
  - Baloxavir Marboxil
  - Sucralose
  - non hazardous compounds
- NZ NZIoC : On the inventory, or in compliance with the inventory
- JP ENCS : Not in compliance with the inventory
- JP ISHL : Not in compliance with the inventory
- KR KECI : Not in compliance with the inventory
- PH PICCS : Not in compliance with the inventory

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**

Version  
2.1

Revision Date:  
04/01/2026

Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

- CN IECSC : Not in compliance with the inventory
- TW TCSI : Not in compliance with the inventory
- US TSCA : Product contains substance(s) not listed on TSCA inventory.
- TH TECI : Not in compliance with the inventory

**TSCA list**


No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION**

**Further information**

**NFPA 704:**



**HMIS® IV / CED:**

<b>HEALTH</b>	<b>*</b>	<b>0</b>
<b>FLAMMABILITY</b>		<b>0</b>
<b>PHYSICAL HAZARD</b>		<b>0</b>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

- NIOSH REL : USA. NIOSH Recommended Exposure Limits
- OSHA CARC : OSHA Specifically Regulated Chemicals/Carcinogens
- NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
- OSHA CARC / PEL : Permissible exposure limit (PEL)

AiIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx -

**XOFLUZA Reconst. Oral Susp. 2 mg/ml**Version  
2.1Revision Date:  
04/01/2026Date of last issue: 01/21/2026  
Date of first issue: 06/15/2025

Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECl - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 04/01/2026

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN / 2504